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BSTRACT
Background:
 
It has been reported that measurements
of eosinophil-derived neurotoxin (EDN) may be useful
to determine eosinophil activities in allergic diseases.
 
Methods:
 
Serum, plasma and urine concentrations of
EDN in patients with allergic diseases were measured
by enzyme-linked immunosorbent assay. Samples of
blood and urine were obtained from the same patients
when their symptoms were active and when patients
were well. The number of eosinophils in peripheral
blood was also counted.
 
Results:
 
The median concentrations of EDN in blood
and urine and the number of eosinophils in peripheral
blood from patients with active symptoms were all sig-
nificantly higher compared with values obtained when
patients were well. Compared with healthy control
subjects, EDN concentrations in the serum, plasma
and urine from asymptomatic asthmatic patients, as
well as EDN concentrations in the serum and plasma
from patients with mild atopic dermatitis and asympto-
matic patients with seasonal allergic rhinitis, were
significantly higher. Blood and urine concentrations of
EDN in patients with active symptoms, but not urine
concentrations of EDN from symptomatic patients with
seasonal allergic rhinitis, were significantly increased
compared with values obtained for healthy control
subjects. The concentrations of EDN in the serum and
plasma from bronchial asthmatic patients, serum from
patients with atopic dermatitis and plasma from
patients with mild atopic dermatitis correlated with the
number of eosinophils in peripheral blood; however,
the concentration of EDN in the serum correlated with
the number of eosinophils from asymptomatic patients
with seasonal allergic rhinitis.
 
Conclusions:
 
Determination of blood and urinary
concentrations of EDN is useful to monitor eosinophil
activity in allergic diseases.
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I
 
NTRODUCTION
 
Eosinophils are important effector cells in allergic
diseases. It can therefore be argued that proper disease
monitoring should include an evaluation of the degree
of eosinophilic inflammation
 
1
 
 in addition to symptom
recording and function measurements. However, direct
assessment of eosinophilic inflammation by means of
biopsies or lavage fluid is not practicable in allergic
diseases clinics. Thus, less invasive markers of eosi-
nophilic inflammation in allergic diseases have been
investigated.
One of the most extensively investigated specific
markers of eosinophils is eosinophil cationic protein (ECP).
Serum concentrations of ECP have been proposed as a
marker of eosinophilic inflammation, especially airway
inflammation in bronchial asthma.
 
2
 
 However, the clinical
usefulness of ECP has been questioned because of prob-
lems in sample processing and considerable variability in
measured values.
 
3
 
 A standardized, well-validated and
generally applicable parameter of eosinophilic inflamma-
tion remains to be fully identified.
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In addition to ECP, activated human eosinophils
secrete several cationic proteins, such as major basic
protein (MBP), eosinophil peroxidase (EPO) and
eosinophil-derived neurotoxin (EDN). Eosinophil-derived
neurotoxin, also called eosinophil protein X (EPX), is 70%
homologous with ECP
 
4–6
 
 and is the only one of the four
basic eosinophil granule proteins that can be accurately
measured in urine.
 
7
 
 In fact, it has been suggested that
urinary EDN may be a valid alternative to measurements
of eosinophil proteins in serum.
 
8
 
We reported an efficient enzyme-linked immuno-
sorbent assay (ELISA) method for measuring specifically
human blood and urinary EDN.
 
9
 
 In addition, we have
shown that the method may be useful to determine the
possible roles of eosinophils in on-going asthma.
 
10
 
 We
have expanded our earlier studies and, in the present
paper, demonstrate that measurements of blood and
urinary concentrations of EDN are useful for monitoring
eosinophil activity in allergic diseases, especially bron-
chial asthma and atopic dermatitis.
 
M
 
ETHODS
 
Subjects
 
Subjects were divided into groups of healthy control
subjects and patients with allergic diseases, such as
bronchial asthma, atopic dermatitis and seasonal aller-
gic rhinitis. The control group comprised 50 subjects (23
males and 27 females) with a median age of 30.0 years
(range 13–66 years) and no personal and/or family
history of allergic disorders. The bronchial asthma group
consisted of 50 patients (30 males and 20 females) with
a median age of 58.0 years (range 1–88 years). The
atopic dermatitis group consisted of 50 patients (33
males and 17 females) with a median age of 15.0 years
(range 1–63 years). The seasonal allergic rhinitis group
consisted of 50 patients (18 males and 32 females) with
a median age of 41.5 years (range 6–72 years).
The diagnosis of bronchial asthma was performed
according to internationally accepted criteria
 
11
 
 after
assessing reversible airway obstruction and/or non-
specific bronchial hyperresponsiveness to methacholine.
Mean screening forced expiratory volume in 1 s (FEV
 
1
 
)
was normal (90.2 
 
±
 
 6.3% of predicted). Bronchial chal-
lenge test with methacholine showed a PD
 
20
 
 FEV
 
1
 
 less
than 1 mg in all subjects. All subjects underwent skin
prick tests with common airborne allergens, such as
house dust, pollens, molds and animal dander, as well
as blood examinations for total IgE levels. All subjects
were free of symptoms for the 2 weeks preceding the
initial test and had no detectable symptoms at the time of
the initial study. In addition to this test, samples of blood
and urine were obtained from the same patients when
they had active symptoms, such as wheezing and breath-
lessness on moderate exercise (FEV
 
1
 
 was 53.8 
 
±
 
 5.9% of
predicted). Patients had been instructed to take only
regular medications before coming to the hospital. They
were treated for the attacks by anti-asthma treatments
after the second test.
The diagnosis of atopic dermatitis was made accord-
ing to the clinical and morphological criteria defined by
Hanifin and Rajka.
 
12
 
 Based on the extent of the skin
lesions involved (erythema, edema and lichenification)
and subjective symptoms, such as pruritus and sleep loss,
samples of blood and urine were obtained from the same
patients when their conditions were mild and when they
were severe.
In the study of seasonal allergic rhinitis, patients with at
least a 1 year history of seasonal allergic rhinitis during
the Japanese cedar season, skin test sensitivity and IgE
test findings positive to Japanese cedar were enrolled.
No patients had perennial rhinitis. The study was per-
formed before and during the Japanese cedar pollen
season. Each patient was asymptomatic before the pollen
season and, during the pollen season, showed active
symptoms such as sneezing, rhinorrhea, nasal conges-
tion, itchy nose and/or throat and itchy eyes. By staining,
the presence of eosinophils in nasal discharge was con-
firmed in each patient during the pollen season.
The present study was approved by the Institutional
Ethics Committee of Gunma Clinical Research Center for
Allergy and Regeneration, Showa Hospital, and written
informed consent was obtained from each individual
before the study commenced.
 
Sampling procedures of blood and urine
 
Because of reports showing circadian variations in
urinary EDN
 
13–15
 
 and serum EDN,
 
15
 
 samples of blood
and urine were obtained in the afternoon of each test
period (13.00–15.00 h). Blood samples for measure-
ment of serum and plasma concentrations of EDN were
collected in Venoject-II Tube Autosep tubes (VP-AS076;
Terumo, Tokyo, Japan) and in Venoject-II tubes that
contained EDTA-3K (VP-TK052; Terumo), respectively,
as described previously.
 
9
 
 Unless otherwise indicated,
samples for the measurement of serum and plasma
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concentrations of EDN were incubated at room temper-
ature (20–25
 
°
 
C) for 1 h and for 30 min, respectively.
Thereafter, the sera and plasma were separated by
centrifugation at 1350 
 
g
 
 for 10 min at 4
 
°
 
C and trans-
ferred to new plastic tubes. Urine samples were also
collected from each individual as a spot sample in the
afternoon. After 30 min of collection, urine samples were
centrifuged at 1350 
 
g
 
 for 10 min at 4
 
°
 
C and transferred
to new plastic tubes. Each sample was aliquoted into a
new plastic tube and stored at –20
 
°
 
C until assay.
 
Sandwich ELISA for EDN
 
We developed an efficient ELISA method for the determi-
nation of EDN
 
9
 
 that has already been introduced onto
the market by Medical and Biological Laboratories Co.
Ltd (Nagoya, Japan). All assays were performed in
duplicate for each sample and mean values are
reported. The concentrations of urinary creatinine (Cr)
were determined with an L-type creatinine-F assay system
(Wako Pure Chemical, Osaka, Japan). The concentra-
tions of urinary EDN are expressed as 
 
µ
 
g/mmol Cr to
correct for urine volume.
 
Counting the number of eosinophils
 
Counting of the number of eosinophils in peripheral
blood was performed automatically by the Beckman
Coulter counter (Beckman Coulter, Fullerton, CA, USA)
and MAXM A/L system (Beckman Coulter).
 
Statistical analysis
 
Results of measurements are presented as the median
(quartile 1–quartile 3) unless indicated otherwise. The
Wilcoxon signed-rank test was used to compare paired
data. Differences between each disease group and the
control group were analyzed with the Mann–Whitney
 
U
 
-test. Correlation coefficients were obtained using the
Spearman’s Rank correlation procedure. Probabilities
less than 5% were considered statistically significant.
 
R
 
ESULTS
 
Eosinophil-derived neurotoxin concentrations 
in serum, plasma and urine from patients with 
allergic diseases when their symptoms were 
active and when patients were well
 
Eosinophil-derived neurotoxin concentrations in the
blood and urine from patients with allergic diseases
were compared when their symptoms were active and
when patients were well. The EDN concentrations in
serum (Fig. 1), plasma (Fig. 2) and urine (Fig. 3) from
patients with allergic diseases, such as bronchial
asthma, atopic dermatitis and seasonal allergic rhinitis,
were significantly higher when their symptoms were
active compared with when they were well.
 
Eosinophil-derived neurotoxin concentrations 
in serum, plasma and urine from patients with 
allergic diseases, as well as from healthy 
control subjects
 
Median (quartile 1–quartile 3) EDN concentrations
in the serum, plasma and urine from asymptomatic
bronchial asthmatic patients were 41.3 ng/mL
(28.5–51.0 ng/mL), 23.4 ng/mL (16.8–29.0 ng/mL) and
75.9 
 
µ
 
g/mmol Cr (47.8–106.9 
 
µ
 
g/mmol Cr), respec-
tively; those from patients with mild atopic dermatitis
were 39.5 ng/mL (26.5–50.0 ng/mL), 19.4 ng/mL (14.3–
26.0 ng/mL) and 66.8 
 
µ
 
g/mmol Cr (40.8–93.5 
 
µ
 
g/
mmol Cr), respectively; and those from asymptomatic
patients with seasonal allergic rhinitis were 28.0 ng/mL
(21.0–35.5 ng/mL), 16.1 ng/mL (12.8–21.5 ng/mL) and
46.6 
 
µ
 
g/mmol Cr (35.0–64.3) 
 
µ
 
g/mmol Cr, respec-
tively. Concentrations of EDN in the serum, plasma and
 
Fig. 1
 
Eosinophil-derived neurotoxin (EDN) concentrations in
serum from patients with bronchial asthma, atopic dermatitis
and seasonal allergic rhinitis. The EDN concentrations were
measured in patients with bronchial asthma as well as seasonal
allergic rhinitis when patients were either asymptomatic (A) or
symptomatic (B), and from patients with either mild (A) or severe
(B) atopic dermatitis. Concentrations of EDN from patients with
allergic diseases were compared when their symptoms were
active and when they were well. **
 
P
 
 < 0.01, *
 
P
 
 < 0.05.
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urine from healthy control subjects were 19.1 ng/mL
(16.0–28.5 ng/mL), 13.8 ng/mL (11.3–18.0 ng/mL) and
61.1 
 
µ
 
g/mmol Cr (36.1–80.3 
 
µ
 
g/mmol Cr), respec-
tively. The concentrations of EDN in the serum, plasma
and urine from asymptomatic asthmatic patients were
significantly elevated compared with values obtained for
healthy control subjects (Fig. 4). The concentrations of
EDN in the serum and plasma from patients with mild
atopic dermatitis (Fig. 5), as well as from asymptomatic
patients with seasonal allergic rhinitis (Fig. 6), were
significantly elevated compared with values obtained for
healthy control subjects.
Median (quartile 1–quartile 3) EDN concentrations in
the serum, plasma and urine from symptomatic bronchial
asthmatic patients were 49.8 ng/mL (29.5–76.0 ng/mL),
28.8 ng/mL (17.8–42.0 ng/mL) and 191.1 
 
µ
 
g/mmol Cr
(133.9–280.7 
 
µ
 
g/mmol Cr); those from patients with
 
Fig. 2
 
Eosinophil-derived neurotoxin (EDN) concentrations in
plasma from patients with bronchial asthma, atopic dermatitis
and seasonal allergic rhinitis. The EDN concentrations were
measured in patients with bronchial asthma as well as seasonal
allergic rhinitis when patients were either asymptomatic (A) or
symptomatic (B), and from patients with either mild (A) or severe
(B) atopic dermatitis. Concentrations of EDN from patients with
allergic diseases were compared when their symptoms were
active and when they were well. **
 
P
 
 < 0.01, *
 
P
 
 < 0.05.
 
Fig. 3
 
Eosinophil-derived neurotoxin (EDN) concentrations in
urine from patients with bronchial asthma, atopic dermatitis and
seasonal allergic rhinitis. The EDN concentrations were meas-
ured in patients with bronchial asthma as well as seasonal
allergic rhinitis when patients were either asymptomatic (A) or
symptomatic (B), and from patients with either mild (A) or severe
(B) atopic dermatitis. Concentrations of EDN from patients with
allergic diseases were compared when their symptoms were
active and when they were well. **
 
P
 
 < 0.01.
 
Fig. 4
 
Eosinophil-derived neurotoxin (EDN) concentrations in
serum, plasma and urine from bronchial asthmatic patients
when they were either asymptomatic (A) or symptomatic (B) and
healthy control subjects (C). Results are presented as the median
(quartile 1–quartile 3). **
 
P
 
 < 0.01, *
 
P
 
 < 0.05.
 
Fig. 5
 
Eosinophil-derived neurotoxin (EDN) concentrations in
serum, plasma and urine from patients with either mild (A) or
severe (B) atopic dermatitis and healthy control subjects (C).
Results are presented as the median (quartile 1–quartile 3).
**
 
P
 
 < 0.01.
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severe atopic dermatitis were 62.8 ng/mL (38.5–
85.0 ng/mL), 28.0 ng/mL (17.5–38.5 ng/mL) and
149.5 
 
µ
 
g/mmol Cr (125.6–235.7 
 
µ
 
g/mmol Cr), respec-
tively; and those from symptomatic patients with seasonal
allergic rhinitis were 41.3 ng/mL (26.5–50.0 ng/mL),
21.8 ng/mL (14.5–25.5 ng/mL) and 65.1 
 
µ
 
g/mmol Cr
(44.7–92.3 
 
µ
 
g/mmol Cr), respectively. The concentra-
tions of EDN in the serum, plasma and urine, except for
EDN concentrations in the urine from symptomatic
patients with seasonal allergic rhinitis, were significantly
elevated in patients with allergic diseases compared with
values obtained for healthy control subjects  (Figs 4–6).
 
Number of eosinophils in peripheral blood 
from patients with allergic diseases when their 
symptoms were active and when patients were 
well
 
The number of eosinophils in peripheral blood was
counted in samples from the same patients when their
symptoms were active and when they were well. Median
values of eosinophils in peripheral blood from asympto-
matic and symptomatic bronchial asthma patients were
372 and 510/mm
 
3
 
, respectively; those from patients
with mild and severe atopic dermatitis were 464 and
701 /mm
 
3
 
, respectively; and those from asymptomatic
and symptomatic patients with seasonal allergic rhinitis
were 197 and 331/mm
 
3
 
, respectively. The number of
 
Fig. 6
 
Eosinophil-derived neurotoxin (EDN) concentrations in
serum, plasma and urine from patients with seasonal allergic
rhinitis when they were either asymptomatic (A) or symptomatic
(B) and healthy control subjects (C). Results are presented as the
median (quartile 1–quartile 3). **
 
P
 
 < 0.01, *
 
P
 
 < 0.05.
 
Fig. 7
 
Relationships in bron-
chial asthmatic patients when
they were either asymptomatic
(a,c,e) or symptomatic (b,d,f)
between the number of eosi-
nophils in peripheral blood and
eosinophil-derived neurotoxin
(EDN) concentrations in serum
(a,b), plasma (c,d) and urine
(e,f). The correlation between
serum EDN concentrations and
the number of eosinophils in
asymptomatic and symptomatic
patients was 
 
r
 
 = 0.660,
 
P
 
 < 0.0001 and 
 
r
 
 = 0.605,
 
P
 
 < 0.0001, respectively. The
correlation between plasma
EDN concentrations and the
number of eosinophils in asymp-
tomatic symptomatic patients
was 
 
r
 
 = 0.527, 
 
P
 
 < 0.0001
and 
 
r
 
 = 0.442, 
 
P
 
 < 0.0001,
respectively.
 364 J MORIOKA 
 
ET AL.
eosinophils in peripheral blood was significantly higher
in patients with allergic diseases when their symptoms
were active compared with when they were well
(
 
P
 
 < 0.05 in bronchial asthma; 
 
P
 
 < 0.01 in atopic
dermatitis and seasonal allergic rhinitis).
 
Relationships between EDN concentrations 
and the number of eosinophils in peripheral 
blood from patients with allergic diseases
 
As shown in Fig. 7, significant relationships were
observed between the concentration of serum EDN/
plasma EDN and the number of eosinophils in periph-
eral blood from asymptomatic patients with bronchial
asthma (
 
r
 
 = 0.660, 
 
P
 
 < 0.0001 and 
 
r
 
 = 0.527,
 
P < 0.0001, respectively) as well as symptomatic
patients with bronchial asthma (r = 0.605, P < 0.0001
and r = 0.442, P < 0.0001, respectively). Significant
relationships were observed between serum EDN con-
centrations and the number of eosinophils in peripheral
blood in patients with mild as well as severe atopic
dermatitis (r = 0.557, P < 0.0001 and r = 0.431,
P < 0.0001, respectively). A significant relationship was
also observed between plasma EDN concentrations and
the number of eosinophils in peripheral blood in patients
with mild atopic dermatitis (r = 0.454, P < 0.0001;
Fig. 8). A significant relationship was observed between
serum EDN concentrations and the number of eosi-
nophils in peripheral blood in asymptomatic patients
with seasonal allergic rhinitis (r = 0.520, P < 0.0001;
Fig. 9).
DISCUSSION
Concepts have been developed that measurements of
eosinophil-derived proteins in serum, especially assess-
ment of serum ECP, may be used to reflect inflammatory
activities of eosinophils in the lungs of patients with
bronchial asthma.2 However ECP is a very sticky and
extremely charged protein16 and the clinical usefulness
of ECP has been questioned because of problems in
sample processing and the considerable variability of
measured values.3
Fig. 8 Relationships in patients
with mild (a,c,e) or severe (b,d,f)
atopic dermatitis between the
number of eosinophils in periph-
eral blood and eosinophil-
derived neurotoxin (EDN) con-
centrations in the serum (a,b),
plasma (c,d) and urine (e,f). The
correlation between serum EDN
concentrations and the number
of eosinophils in patients with
mild or severe atopic dermatitis
was r = 0.557, P < 0.0001
and r = 0.431, P < 0.0001,
respectively. The correlation
between plasma EDN concen-
trations and the number of
eosinophils in patients with mild
atopic dermatitis was r = 0.454,
P < 0.0001.
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Eosinophil-derived neurotoxin, also called EPX, pos-
sesses high sequence homology to ECP4–6 and is the only
one of the four basic eosinophil granule proteins that can
be measured accurately in urine.7 In fact, it has been
reported that urinary EDN may be a valid alternative to
measurements of eosinophil proteins in serum.8 Recent
studies have indicated the usefulness of measuring
concentrations of urinary EPX in monitoring childhood
bronchial asthma17,18 and atopic dermatitis in children
and adults,19–21 and measurement of blood EPX in moni-
toring seasonal allergic rhinitis.22 However, we are not
aware of any report indicating differences in blood and
urinary EDN concentrations from patients with allergic
diseases.
We have reported an efficient ELISA method for meas-
uring specifically human blood and urinary EDN.9 In
addition, we have shown that the method may be useful
to determine the possible roles of eosinophils in on-going
asthma.10 We have expanded our earlier studies and, in
the present paper, have demonstrated that EDN concen-
trations in blood and urine, as well as the number of eosi-
nophils in peripheral blood, from patients with allergic
diseases were significantly higher when their symptoms
were active compared with those when they were well.
Concerning EDN concentrations in the blood, the EDN
concentrations in the serum were higher than those in the
plasma, irrespective of the allergic disease. We could not
investigate the mechanisms of this finding in the present
study. However, it is well known that sample processing
conditions can affect ECP blood levels23,24 and serum
levels of ECP represent the levels found in vivo plus addi-
tional proteins released in vitro from peripheral blood
eosinophils during the coagulation period.25,26 So, the
same mechanisms may be involved in the case of EDN
and further studies are required. In any case, our data
support previous reports that urinary EPX may reflect
disease activity and that measurements of urinary EPX
may reflect inflammatory activities of eosinophils in child-
hood bronchial asthma,17,18 as well as atopic dermatitis
in children and adults.19–21 However, these studies were
performed in a single allergic disease. Therefore, the
question remains as to whether there are differences in
blood and urinary EDN concentrations among the aller-
gic diseases.
Fig. 9 Relationships in patients
with seasonal allergic rhinitis
when they were either asympto-
matic (a,c,e) or symptomatic
(b,d,f) between the number of
eosinophils in peripheral blood
and eosinophil-derived neuro-
toxin (EDN) concentrations in
serum (a,b), plasma (c,d) and
urine (e,f). The correlation
between serum EDN concentra-
tions and the number of eosi-
nophils in asymptomatic patients
was r = 0.520, P < 0.0001.
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As the next step, we examined differences in blood and
urinary EDN concentrations between patients with aller-
gic diseases and healthy control subjects. The concen-
trations of blood and urinary EDN were increased in
bronchial asthmatic patients, irrespective of their con-
dition (symptomatic or asymptomatic), compared with
healthy control subjects. Eosinophil-derived neurotoxin
concentrations in the serum and plasma from patients
with mild atopic dermatitis, as well as asymptomatic
patients with seasonal allergic rhinitis, were increased
compared with values obtained for healthy control sub-
jects. In addition, EDN concentrations in the blood and
urine from patients with active symptoms, except for EDN
concentrations in the urine from symptomatic patients
with seasonal allergic rhinitis, were significantly increased
compared with values obtained for healthy control sub-
jects. There were no differences in urinary EDN concen-
trations between healthy control subjects and patients
with seasonal allergic rhinitis, irrespective of their symp-
toms. In fact, it has been shown that EPX concentrations
in serum and plasma are related to symptoms in patients
with seasonal allergic rhinitis.22
Finally, we examined the relationship between EDN
concentrations and the number of eosinophils in periph-
eral blood from patients with allergic diseases. Eosinophil-
derived neurotoxin concentrations in serum and plasma
from bronchial asthmatic patients were significantly cor-
related with the number of peripheral blood eosinophils,
irrespective of their clinical symptoms. The EDN concen-
trations in the serum and plasma from patients with mild
atopic dermatitis were significantly correlated with the
number of peripheral blood eosinophils. However, in
patients with seasonal allergic rhinitis, only EDN concen-
trations in the serum from asymptomatic patients were
significantly correlated with the number of eosinophils in
peripheral blood. The reason why EDN concentrations
from symptomatic patients did not correlate with the
number of eosinophils in peripheral blood remains
unknown. However, taken together with the result men-
tioned above that there were no differences in urinary
EDN concentrations between healthy control subjects
and patients with seasonal allergic rhinitis irrespective of
their symptoms, the degree of eosinophilic inflammation
in seasonal allergic rhinitis may be less compared with
that in bronchial asthma and atopic dermatitis and meas-
uring the number of eosinophils in the peripheral blood
may not be useful in assessing the inflammatory pro-
cesses of seasonal allergic rhinitis. Further studies are
required to clarify this point.
In conclusion, we are the first to report differences in
blood and urinary EDN concentrations from patients
with allergic diseases. Our findings demonstrate that
measurements of blood and urinary EDN concentra-
tions are useful for monitoring eosinophil activity in
allergic diseases.
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